Michail_Petrov-96
Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug candidate ANB032 due to disappointing clinical results.
The biotech company said a Phase 2b study of ANB032 failed to meet its